CAS: 544-35-4; (9Z,12Z)-Ethyl Octadeca-9,12-Dienoate

上下游产品

ethanol linoleic acid (Z)-3-nonenal 5-phosphanylidene)-nonanoic acid ethyl ester9-(Triphenyl-λ5-phosphanylidene)-nonanoic acid ethyl esterazelaic acid monoethyl ester Linoleyl alcohol (9Z,12Z)-°Ctadeca-9,12-dienal azelaic acid

octadeca-9,12-Diinsaeureethylester置于lindlar'S Catalyst 喹啉,氢气体系中,用 Petroleum Ether 作为反应溶剂,化学反应生成 亚油酸乙酯
参考文献:Osbond,J.M. Et Al.,Journal Of The Chemical Society,1961,P. 2783-2787
标题:Osbond,J.M. Et Al.,Journal Of The Chemical Society,1961,P. 2783-2787

专利信息

专利号:US-2005233427-A1
优先权日:2004-03-31
标题 :Processes for the production of triglycerides of unsaturated fatty acids in the presence of enzymes
发明人：SCHOERKEN ULRICH; MEYER CAROLIN; BOTH SABINE; HORLACHER PETER
权利人:SCHOERKEN ULRICH; MEYER CAROLIN; BOTH SABINE; HORLACHER PETER
摘要:Processes for the enzyme-catalyzed synthesis of triglycerides containing polyunsaturated fatty acids in which the synthesis is preceded by a pre-hydrolysis in which (a) C 1-4 alkyl esters of polyunsaturated fatty acids are completely or partly hydrolyzed in vacuo with continuous addition of water or are partly hydrolyzed in several stages without vacuum, (b) after the hydrolysis, the water is removed by separation or distillation and (c) the synthesis of the polyunsaturated fatty acids with glycerol in vacuo in the presence of an enzyme to form their triglycerides is carried out under low-water conditions, (d) the enzymes are removed from the triglyceride by separation or filtration and (e) the remaining fatty acids and/or possible residues of C 1-4 alkyl esters are removed from the triglyceride by distillation or refining; the pre-hydrolysis and the subsequent synthesis preferably being carried out as a one-pot process in the same reactor and in the presence of the same enzyme.

专利号:US-12295961-B2
优先权日:2009-12-31
标 题:Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols
发明人：DHINGRA OM
权利人:MARIUS PHARMACEUTICALS INC
摘要:A formulation for drug delivery, providing enhanced modulation of solubility, stability, absorption, metabolism, and/or pharmacokinetic profile of a lipophilic therapeutic agent by formulation with sterols and/or sterol esters, resulting in higher bioavailability of a therapeutic agent administered to a subject in need of such therapeutic agent. The formulation contains a therapeutic agent and a sterol or sterol ester, and can, optionally, further contain a solubilizer and/or an enhancing agent. Also described are pharmaceutical compositions containing the formulations and methods of making and methods of using the formulations and pharmaceutical compositions. Formulations of the disclosure can be constituted to minimize the synthesis of dihydrotestosterone when the therapeutic agent includes testosterone or testosterone esters.

专利号:US-9193665-B2
优先权日:2013-05-27
标题 :Synthesis of galanal compounds and analogues thereof
发明人：CHEIN RONG-JIE
权利人:ACADEMIA SINICA
摘要:The present disclosure provides methods of preparing glucagon-like peptide-1 (GLP-1) receptor modulators, such as compounds of Formula (II) or (VI), or intermediates thereof. The compounds that may be prepared by the described methods are useful for regulating blood glucose levels and/or treating a disease mediated by a GLP-1 receptor (e.g., diabetes).

专利号:US-7344868-B2
优先权日:2003-06-03
标题:Method for synthesizing ceramide-type compounds
发明人：LASSALLE LAURENT; YVERGNAUX FLORENT
权利人:LASSALLE LAURENT; YVERGNAUX FLORENT
摘要:The invention relates to the fields of fatty substance chemistry, specifically of the ceramide-type compound synthesis. The invention resides substantially in the synthesis of ceramide-type compounds. Specifically, the aim of the invention is a new enzymatic synthesis method, comprising at least one amidification step and one esterification step, achieved through lipases, among fatty acids and/or esters thereof and amino alcohols. The resulting ceramide-type compounds can be used as cosmetic and/or pharmaceutical compositions, in particular as dermatological compositions in conjunction or in admixture with one or more suitable cosmetic and/or pharmaceutical excipients or carriers. The method has an interest particularly in the synthesis of active compounds useful in the fields of cosmetology and/or pharmacology and specifically of dermatology.

专利号:US-11617758-B2
优先权日:2009-12-31
标 题 :Emulsion formulations
发明人：DHINGRA OM; BERNSTEIN JAMES S
权利人:MARIUS PHARMACEUTICALS LLC
摘要:A SEDDS or SMEDDS or SNEDDS formulation for drug delivery of a lipophilic therapeutic agent, providing enhanced modulation of solubility, stability, absorption, metabolism, and/or pharmacokinetic profile of the therapeutic agent by formulation with a lipophilic surfactant, a hydrophilic surfactant, one or more solubilizers and, optionally, digestible oils, resulting in higher bioavailability of the therapeutic agent administered to a subject in need of such therapeutic agent. Also described are pharmaceutical compositions containing the formulations and methods of making and methods of using the formulations and pharmaceutical compositions. Formulations of the disclosure can be constituted to minimize the synthesis of dihydrotestosterone when the therapeutic agent includes testosterone or testosterone esters.

专利号:US-2013303495-A1
优先权日:2009-12-31
标题:Emulsion formulations
发明人：DHINGRA OM; BERNSTEIN JAMES S
权利人:SOV THERAPEUTICS; DIFFERENTIAL DRUG DEV ASSOCIATES LLC
摘要:A SEDDS or SMEDDS or SNEDDS formulation for drug delivery of a lipophilic therapeutic agent, providing enhanced modulation of solubility, stability, absorption, metabolism, and/or pharmacokinetic profile of the therapeutic agent by formulation with a lipophilic surfactant, a hydrophilic surfactant, one or more solubilizers and, optionally, digestible oils, resulting in higher bioavailability of the therapeutic agent administered to a subject in need of such therapeutic agent. Also described are pharmaceutical compositions containing the formulations and methods of making and methods of using the formulations and pharmaceutical compositions. Formulations of the disclosure can be constituted to minimize the synthesis of dihydrotestosterone when the therapeutic agent includes testosterone or testosterone esters.